RUNX1-RUNX1T1 AML1-ETO t(8;21) Quantitative Test
Understanding the RUNX1-RUNX1T1 Genetic Test
The RUNX1-RUNX1T1 AML1-ETO t(8;21) Quantitative Test represents a cutting-edge advancement in molecular diagnostics for acute myeloid leukemia (AML). This sophisticated genetic analysis detects and precisely quantifies the specific chromosomal translocation between chromosomes 8 and 21, which creates the RUNX1-RUNX1T1 fusion gene. This genetic abnormality is one of the most common and well-characterized mutations in AML, occurring in approximately 5-12% of all AML cases.
This quantitative test provides healthcare professionals with critical information about disease burden, treatment response, and potential relapse risk. By measuring the exact amount of fusion gene present in patient samples, clinicians can monitor treatment effectiveness and make data-driven decisions about ongoing care strategies.
What Does This Test Measure?
The RUNX1-RUNX1T1 Quantitative Test specifically detects and measures:
- The presence of the t(8;21) chromosomal translocation
- The RUNX1-RUNX1T1 fusion gene expression levels
- Quantitative measurement of minimal residual disease (MRD)
- Treatment response monitoring capabilities
- Early detection of potential relapse
Using advanced Real Time PCR technology, this test provides highly sensitive and specific detection of the genetic abnormality, allowing for precise quantification even at very low levels. The test requires bone marrow or peripheral blood samples collected in EDTA Vacutainers and provides results within 3-4 days.
Who Should Consider This Test?
Clinical Indications and Symptoms
This test is recommended for individuals experiencing:
- Unexplained fatigue, weakness, or pallor
- Frequent infections or fever without obvious cause
- Easy bruising or unusual bleeding
- Bone pain or tenderness
- Unexplained weight loss
- Enlarged lymph nodes, liver, or spleen
- Newly diagnosed acute myeloid leukemia
- Monitoring treatment response in known AML cases
- Suspected relapse in previously treated AML patients
Key Benefits of the RUNX1-RUNX1T1 Test
Choosing this advanced genetic test provides numerous clinical advantages:
- Precise Diagnosis: Confirms the specific genetic subtype of AML
- Treatment Guidance: Helps determine the most effective therapeutic approach
- Prognostic Information: Provides valuable insights into disease progression and outcomes
- Minimal Residual Disease Monitoring: Detects low levels of disease not visible through conventional methods
- Early Relapse Detection: Identifies recurrence before clinical symptoms appear
- Personalized Medicine: Enables tailored treatment strategies based on individual genetic profiles
Understanding Your Test Results
Interpreting Quantitative Measurements
Your test results will provide quantitative measurements of the RUNX1-RUNX1T1 fusion gene:
- Positive Result: Indicates the presence of the t(8;21) translocation, confirming this specific AML subtype
- Quantitative Levels: Higher levels typically correlate with greater disease burden
- Treatment Response: Decreasing levels indicate positive response to therapy
- Minimal Residual Disease: Persistent low levels may indicate residual leukemia cells
- Relapse Monitoring: Rising levels after treatment may signal disease recurrence
It’s essential to discuss your results with your healthcare provider, who will interpret them in the context of your overall clinical picture, treatment history, and other diagnostic findings.
Test Pricing and Availability
| Price Type | Amount (USD) |
|---|---|
| Discount Price | $150 |
| Regular Price | $200 |
Nationwide Availability
GGC DNA has testing facilities conveniently located throughout the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many other cities. Our nationwide network ensures accessible genetic testing services for patients across the country.
Book Your Test Today
Take control of your health with advanced genetic testing from GGC DNA. Our experienced team is ready to assist you with scheduling your RUNX1-RUNX1T1 AML1-ETO t(8;21) Quantitative Test. Contact us today to book your appointment and take the first step toward precise diagnosis and personalized treatment planning.
Call or WhatsApp: +1(267) 388-9828
Our genetic specialists are available to answer your questions and guide you through the testing process. With rapid 3-4 day turnaround times and comprehensive result interpretation, GGC DNA provides the reliable genetic testing services you need for informed healthcare decisions.
